DMAAMEDIUM SIGNALMANAGEMENT10-K

DMAA experienced a CFO resignation in October 2025 while progressing through typical SPAC milestones including unit separation and share count adjustments.

The departure of CFO Glenn Worman represents a notable management change during a critical period for this pharmaceutical-focused SPAC. The timing coincides with the company's progression toward completing its initial business combination, where financial leadership continuity is typically valued by investors and target companies.

Comparing 2026-04-15 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

The balance sheet showed improvement with current liabilities declining meaningfully from $796K to $376K, suggesting better working capital management or resolution of near-term obligations. The overall financial position appears stable for a SPAC in the pre-combination phase, with the liability reduction providing additional financial flexibility as the company pursues acquisition targets.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
-52.7%
$796K→$376K

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-04-15
PRIOR — 2025-03-31
ADDED
As of April 15, 2026, the registrant had 33,717,143 ordinary shares outstanding (inclusive of shares included in outstanding units).
On June 17, 2024, we issued to Drugs Made In America Acquisition LLC, our sponsor, an aggregate of 22,361,111 ordinary shares (the founder shares ) for an aggregate purchase price of $35,000, or approximately $0.0016 per share.
Simultaneously with the closing of the IPO, we consummated the private placement with our sponsor of 400,000 units (the Private Placement Units ) at a price of $10.00 per unit, for $4,000,000.
There is no guarantee that our shareholders at the extraordinary general meeting will approve this proposal.
Recent Developments The ordinary shares and rights comprising the units began separate trading on February 25, 2025.
+7 more — sign up free →
REMOVED
As of March 28, 2025, the registrant had 33,517,143 ordinary shares outstanding (inclusive of shares included in outstanding units).
On June 17, 2024, we issued to the sponsor an aggregate of 22,361,111 ordinary shares (the founder shares ) for an aggregate purchase price of $35,000, or approximately $0.0016 per share.
Our initial business combination and value creation strategy will be to identify, acquire and, after our initial business combination, assist in the growth of a pharmaceutical business in the United States.
Business Strategy Our acquisition and value creation strategy is to identify, acquire and, after our initial business combination, further accelerate the growth of a company in the pharmaceutical industry.
We believe our management team s knowledge, decades of experience and relationships across this industry can effect a positive transformation or augmentation of an existing business model through implementing proven business strategies within the pharmaceutical industry.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →